Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer

  • Authors:
    • Riki Okita
    • Yoshiyuki Yamaguchi
    • Masahiro Ohara
    • Katsuji Hironaka
    • Makoto Okawaki
    • Ichiro Nagamine
    • Takuhiro Ikeda
    • Akiko Emi
    • Jun Hihara
    • Morihito Okada
  • View Affiliations

  • Published online on: February 1, 2009     https://doi.org/10.3892/ijo_00000182
  • Pages: 563-572
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The CD4+CD25high regulatory T (Treg) cells have been demonstrated to negatively modulate anti-tumor immune responses in cancer patients. In this study, effects of low dose anti-CD25 antibody (Ab) to attenuate Treg cells were investigated in cancer patients in vitro and in vivo. Peripheral blood mononuclear cells (PBMCs) from cancer patients were cultivated in vitro in the presence of a high-affinity chimeric anti-CD25 Ab (basiliximab). The CD4+CD25high population, interferon-gamma (IFN-γ) production and FOXP3 expression were analyzed using flow cytometry (FCM), enzyme-linked immunosorbent assay and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, respectively. During in vivo studies, basiliximab was administered intravenously on day 1, followed by AIT using autologous activated lymphocytes on day 8, and the treatment cycle was repeated. Subjective and objective effects were observed, and patients' PBMCs were subjected to FCM and RT-PCR analysis. In vitro analysis revealed that a low concentration of 0.01 µg/ml basiliximab reduced almost all of CD4+CD25high cells, but less of the CD4+ CD25low cells, and augmented IFN-γ production of activated PBMCs. FOXP3 mRNA expression of PBMCs was not affected with or without basiliximab. An in vivo study of 9 metastatic cancer patients (7 colorectal and 2 esophageal) demonstrated no subjective or objective adverse effects, even under repeated administration of basiliximab. The results suggested that low-dose basiliximab can safely be administered repeatedly, and can target CD4+CD25high Treg cells whilst relatively preserving CD4+CD25low activated T cells. The host conditioning with low-dose basiliximab may augment the efficacy of AIT for cancer using activated autologous lymphocytes.

Related Articles

Journal Cover

February 2009
Volume 34 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Okita, R., Yamaguchi, Y., Ohara, M., Hironaka, K., Okawaki, M., Nagamine, I. ... Okada, M. (2009). Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer. International Journal of Oncology, 34, 563-572. https://doi.org/10.3892/ijo_00000182
MLA
Okita, R., Yamaguchi, Y., Ohara, M., Hironaka, K., Okawaki, M., Nagamine, I., Ikeda, T., Emi, A., Hihara, J., Okada, M."Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer". International Journal of Oncology 34.2 (2009): 563-572.
Chicago
Okita, R., Yamaguchi, Y., Ohara, M., Hironaka, K., Okawaki, M., Nagamine, I., Ikeda, T., Emi, A., Hihara, J., Okada, M."Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer". International Journal of Oncology 34, no. 2 (2009): 563-572. https://doi.org/10.3892/ijo_00000182